Welcome to BioSeeker Group!

Ovarian Cancer Drug Pathway Analyzer

Additional Information

Published Date Aug 9, 2016
PDF Fact Sheet View Fact Sheet for the report Ovarian Cancer Drug Pathway Analyzer in PDF
Format Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group
Product Line View All Available Drug Pathway Analyzer Reports

Availability: In stock

$2,250.00

Quick Overview

There are today at least 439 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways for the treatment of ovarian cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 291 drug targets that are included in this drug-pathway analyzing tool. No less than 275 of these have been recorded with mutations and 51 drug targets have mutations which have been causally implicated in cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Ovarian Cancer Drug Pathway Analyzer.

    To find out more about Ovarian Cancer Drug Pathway Analyzer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Ovarian Cancer Drug Pathway Analyzer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or
Extra value: One year of free online updates included with this product

There are today at least 439 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways for the treatment of ovarian cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 291 drug targets that are included in this drug-pathway analyzing tool. No less than 275 of these have been recorded with mutations and 51 drug targets have mutations which have been causally implicated in cancer.

Pathway CoveragePipeline Coverage
BioCarta# 243 Pathways
KEGG# 189 Pathways
NCI-Nature# 250 Pathways
NetPath# 32 Pathways
Marketed# 26
Pre-registration# 1
Phase III# 18
Phase II# 133
Phase I# 109
Preclinical# 124
Discovery# 8
No Data# 10
Suspended# 6
Ceased# 120

The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology of disease and therapeutics to actionable pipeline decisions to ensure that the optimal market conditions exist by the time a candidate drug is commercialized.

For this reason BioSeeker, a leader in pipeline analytics, has constructed this high-level drug-pathway analyzer which lets you interact with the ovarian cancer pipeline in a whole different than way than you ever done before. Its capabilities moves you beyond powerful competitive intelligence to an opportunity seeking tool which lets you, by means of both present and emerging scientific knowledge, analyze the ovarian cancer pipeline for interesting compounds which affect and/or fit your purposes, may it be benchmarking, in/out-licensing, combination therapy options, drug repositioning, indication expansion etc.

You Use this Analyzer Tool in Ovarian Cancer to:

* Map the competition and find suitable benchmarking/licensing drugs based on specific pathways and drug properties

* Uncover potential indication expansion areas for your drug portfolio

* Reveal repositioning opportunities for your older, shelved drugs

* Evaluate the progression and success of targeting certain pathways by different tumor types

* Investigate drugs which affect crosstalk between key pathways

* Investigate different combination therapy options available to you in various cancer types. Use this tool to look for the most-efficient ways to combine your drug with other targeted agents.

* Find possible adjuvant therapy settings with other drugs.

This is how you do it:
In analyzing drug-pathway relationships this tool has three core modes:

1. Select - You go right ahead and select any pathway for analysis

2. Suggest - The tool can suggest pathways to you according to your pipeline specifications

3. Compare - You can overlay any pathways with each other and do a comparative analysis

You can interactively analyze any ovarian cancer drug-pathway relationship by using up to four different pathway sources and further refine your analysis with up to 20 different pipeline parameters, including parameters such as presence of mutations, molecular function of targets, stage of development, sub-cellular localization and many more. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.

The following short video playlist demonstrates the use of the Pathway Analyzer when you know what pathways you are interested in, when you are unsure of which pathways you should be interested in and when you want to compare pathways. It also details what you can expect from a drug profile result.



User Reports with Graphics
Each analysis report generated in the Drug Pathway Analyzer includes many different types of graphs and tables which can also be easily downloaded and dropped into applications such as PowerPoint for external presentations outside the tool.




The Pathway Analyzer Comes Integrated with Pipeline Information
With a simple click you can easily and quickly get relevant information about the drug being included in a specific pathway. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms.
Principal Company & Partners Presentation of principal Company and partners.
Target and Molecular Function of Target Described target(s) is/are presented with:
Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Mutation All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
Biological Structures The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status.

Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight.
Patent Data Available patent information related to the drug is presented here.
Fillings and Approvals Approvals and submissions
Analyst comments
Deals and Licensing Collaborations and deals
Availability for licensing
Phase IV Data Available Phase IV development data, developmental history and scientific data.
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Phase 0 Data Available Phase 0 development data, developmental history and scientific data.
Preclinical Data Available Preclinical data, developmental history and scientific data.
Discovery Data Available discovery development data, developmental history and scientific data., developmental history and scientific data.

System Requirements - Operating system: Windows (2000/XP/Vista/7/8) and Mac Users are offered Online Access Only
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Ovarian Cancer Drug Pathway Analyzer.
    To find out more about Ovarian Cancer Drug Pathway Analyzer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Ovarian Cancer Drug Pathway Analyzer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Drugs' category:


Calcium Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 276 companies plus partners who are today developing 335 calcium signaling pathway targeting drugs in 1110 developmental projects in cancer across 145 different targets. In addition, there is 1 suspended drug and another 130 drugs where development has been ceased. Learn More


Immunotherapy in Oncology: Drug Pathway Analyzer
There are today at least 1183 immunotherapy drugs known to affect more than 237 specific intracellular signaling pathways for the treatment of more than 175 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 452 drug targets that are included in this drug-pathway analyzing tool. No less than 419 of these have been recorded with mutations and 57 drug targets have mutations which have been causally implicated in cancer. Learn More

Other selected research from the 'R&D' category:


Proteins in Oncology Drug Pipeline Update
BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More


Renal Cancer Drug Pathway Analyzer
There are today at least 304 targeted molecular therapies known to affect more than 240 specific intracellular signaling pathways for the treatment of renal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 223 drug targets that are included in this drug-pathway analyzing tool. No less than 215 of these have been recorded with mutations and 46 drug targets have mutations which have been causally implicated in cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Prostate Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Drug Pathway Analyzer' category:


Pancreatic Cancer Drug Pathway Analyzer
There are today at least 406 targeted molecular therapies known to affect more than 253 specific intracellular signaling pathways for the treatment of pancreatic cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 317 drug targets that are included in this drug-pathway analyzing tool. No less than 306 of these have been recorded with mutations and 62 drug targets have mutations which have been causally implicated in cancer. Learn More


Immunotherapy in Oncology: Drug Pathway Analyzer
There are today at least 1183 immunotherapy drugs known to affect more than 237 specific intracellular signaling pathways for the treatment of more than 175 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 452 drug targets that are included in this drug-pathway analyzing tool. No less than 419 of these have been recorded with mutations and 57 drug targets have mutations which have been causally implicated in cancer. Learn More